ClinicalTrials.gg
CompletedNCT06082869Updated Oct 13, 2023

Evaluation and Comparison of a Novel Dentrifice Formulation on Plaque Removal

An Early Phase 1 interventional study of Protegera™ toothpaste (NaF) and Crest™ Cavity Protection toothpaste (NaF) in Dental Plaque, sponsored by Protegera, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-13.

Sponsored by Protegera, Inc. · Early Phase 1, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Feb 2023, 3 years 8 months ago, and no results have been posted to the registry.
  • Registered 8 months after the study started (first participant enrolled Jan 2023, registered Oct 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 65 studies in Dental Plaque with a site in United States — 7 open to participants now, 8 under way, 1 of them phase 3. Dental Plaque · United States.

Enrollment
27th of 59
82 · median 80
Started
2023
with 3 others
Phase 1
5 of 65
none open now
Registered
45th of 65
by date

Among the 65 studies in Dental Plaque with a site in United States, this one is the 27th largest by enrollment of the 59 interventional ones that give a count, is one of 4 that started in 2023, is one of 5 in phase 1, and was the 45th registered.

Dental Plaque

352 studies on the registry are indexed under Dental Plaque; 60 are open to participants now.

Browse Dental Plaque studies →

Open to participants now

7 of the 65 studies in Dental Plaque with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 35 Dental Plaque studies recruiting now, 10 (29%) set no upper age limit and 20 (57%) stop at 75 or younger; 14 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 69 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Dental Plaque with a site in United States, or all of them as a file.
02

Study summary

To evaluate and compare plaque removal efficacy and safety of a novel dentifrice formulation immediately after the first supervised use and following one week of twice, daily use at home.

Read the detailed description

Study participants brushed their teeth for one minute, two times daily, for seven days.

Participants who met study entry criteria were randomized to either the test (Protegera™) or control (Crest™ Cavity Protection) toothpaste, and each were given the same straight, soft bristled toothbrush to use throughout the study.

On Day 1, participants were given an oral exam, and a pre-brushing plaque score was recorded. Participants then brushed their teeth for one minute under supervision, and a post-brushing plaque score was recorded.

On Day 7, participants were given an oral exam, and a pre-brushing plaque score was recorded. Participants then brushed their teeth for one minute under supervision, and a post-brushing plaque score was recorded.

03

Conditions studied

  • Dental Plaque

Browse trials for

04

Who can participate

Ages eligible
18 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have been males and females aged 18 to 69, in good general health.
  2. Have read and signed an Form.
  3. Have been in good health based on medical history review by the Principal Investigator.
  4. Have had a minimum of 18 natural teeth with scorable facial and lingual surfaces. Teeth that were grossly carious, orthodontically banded, restorations such as crowns, veneers or implants, exhibit general cervical abrasion and/or enamel abrasion, or third molars were not included in the tooth count.
  5. (If female of child bearing age) have been using an established method of (systemic contraceptives such as birth control pills, injectable contraceptive or patch contraceptives, partner with vasectomy, condom with additional spermicide, IUD or abstinence).
  6. Have had a mean full-mouth pre-brushing plaque score (Soparkar Modification1 of the Turesky Modification2 of the plaque index of Quigley and Hein.3) of ≥ 2.00 at the baseline visit.
  7. Have agreed not to have a dental prophylaxis or any other elective, non-emergency dental procedures (other than those provided during the study) any time during the 7-day study.
  8. Have been willing to refrain from all oral hygiene procedures (including chewing gum) for 24 hrs. and refrained from eating, drinking and smoking for approximately 2 hours prior to Visits 1 \& 2.
  9. Have agreed to refrain from use of all oral hygiene products (i.e., floss, mouthwash, etc.), other than the toothbrush and toothpaste supplied, for the duration of the 7-day study.
  10. Have agreed to comply with the conditions and schedule of the study.

Exclusion criteria

Exclusion Criteria:

  1. Had any known allergies or sensitivities to marketed dentifrice or oral hygiene products.
  2. Had any physical limitations or restrictions which might preclude normal tooth brushing.
  3. Had existing serious medical condition or transmittable disease as determined after review of the medical history form. These will include but not be limited to: active hepatitis, tuberculosis, AIDS, asthma, bleeding disorder, diabetes, cirrhosis, leukemia, renal disease, sarcoidosis, vascular disease, thrush, or leukoplakia.
  4. Self-reported as pregnant or nursing female.
  5. Required antibiotic therapy within 30-days prior to study treatment.
  6. Had a history of adverse effects, oral soft or hard tissue sensitivity, to any ingredient in the test materials.
  7. Had received therapy with any medications, currently or within the last 30 days, which might interfere with the outcome of the study by affecting tissue condition, or salivation, particularly chronic therapy or long-term use, as determined by the investigator.
  8. Had severe periodontal disease or being actively treated for periodontal disease.
  9. Had fixed or removable orthodontic appliances, bridges, peri/oral piercings, or removable partial dentures.
  10. Had significant oral soft tissue pathology based on a visual examination baseline.
  11. Had evidence of poor oral hygiene or rampant dental caries or presence of extrinsic stain or calculus deposits that may interfere with plaque assessments.
  12. Had received a dental prophylaxis within 30-days prior to Visit 1.
  13. Had participated in another dental research study within 30-days prior to Visit 1.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Early Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    Experimental

    Protegera™ toothpaste (NaF), brushing twice daily for one minute

    Drug: Protegera™ toothpaste (NaF)

  • Active comparator
    Control

    Crest™ Cavity Protection toothpaste (NaF), brushing twice daily for one minute

    Drug: Crest™ Cavity Protection toothpaste (NaF)

Interventions

06

What researchers measure

Primary outcomes

  1. Change In Dental Plaque

    Plaque measured on a scale of 0 to 5; 0 = No plaque; 5 = 2/3rd or more of tooth covered with plaque

    Time frame: Day 1 and Day 7 of manual brushing

  2. Changes in oral soft or hard tissues

    Examination of the oral cavity to determine any changes in color, soft tissue abrasion, texture or other irregularities

    Time frame: Day 1 and Day 7

07

Study locations

1 site
  • Salus Research, Inc
    Fort Wayne, Indiana 46825, United States
08

References and documents

Publications

  • Lobene RR, Soparkar PM, Newman MB. Use of dental floss. Effect on plaque and gingivitis. Clin Prev Dent. 1982 Jan-Feb;4(1):5-8. No abstract available. PubMed 6980082 ↗
  • Turesky S, Gilmore ND, Glickman I. Reduced plaque formation by the chloromethyl analogue of victamine C. J Periodontol. 1970 Jan;41(1):41-3. doi: 10.1902/jop.1970.41.41.41. No abstract available. PubMed 5264376 ↗
  • QUIGLEY GA, HEIN JW. Comparative cleansing efficiency of manual and power brushing. J Am Dent Assoc. 1962 Jul;65:26-9. doi: 10.14219/jada.archive.1962.0184. No abstract available. PubMed 14489483 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Feb 2023, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2023
First posted
Oct 13, 2023
StartActual
Jan 30, 2023
Primary completionActual
Feb 23, 2023
CompletionActual
Feb 23, 2023
Last update
Oct 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06082869
Lead sponsor
Protegera, Inc.
Responsible party
Sponsor
First posted
Oct 13, 2023
Start date
Jan 30, 2023
Primary completion
Feb 23, 2023
Completion
Feb 23, 2023
Last update
Oct 13, 2023

Study contacts

Jeffery L Milleman, DDS, MPA
principal investigator · Salus Research, Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium Fluoride

Start the discussion